BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

718 related articles for article (PubMed ID: 17854865)

  • 1. Dysfibrinogen Kagoshima with the amino acid substitution gammaThr-314 to Ile: analyses of molecular abnormalities and thrombophilic nature of this abnormal molecule.
    Niwa K; Mimuro J; Miyata M; Sugo T; Ohmori T; Madoiwa S; Tei C; Sakata Y
    Thromb Res; 2008; 121(6):773-80. PubMed ID: 17854865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombophilic dysfibrinogen Tokyo V with the amino acid substitution of gammaAla327Thr: formation of fragile but fibrinolysis-resistant fibrin clots and its relevance to arterial thromboembolism.
    Hamano A; Mimuro J; Aoshima M; Itoh T; Kitamura N; Nishinarita S; Takano K; Ishiwata A; Kashiwakura Y; Niwa K; Ono T; Madoiwa S; Sugo T; Matsuda M; Sakata Y
    Blood; 2004 Apr; 103(8):3045-50. PubMed ID: 15070682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrinogen Bastia (gamma 318 Asp-->Tyr) a novel abnormal fibrinogen characterized by defective fibrin polymerization.
    Lounes KC; Soria C; Valognes A; Turchini MF; Soria J; Koopman J
    Thromb Haemost; 1999 Dec; 82(6):1639-43. PubMed ID: 10613648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibrinogen St. Gallen I (gamma 292 Gly--> Val): evidence for structural alterations causing defective polymerization and fibrinogenolysis.
    Stucki B; Schmutz P; Schmid L; Haeberli A; Lämmle B; Furlan M
    Thromb Haemost; 1999 Feb; 81(2):268-74. PubMed ID: 10064005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel Asp344Val substitution in the fibrinogen gamma chain (fibrinogen Caen) causes dysfibrinogenemia associated with thrombosis.
    Robert-Ebadi H; Le Querrec A; de Moerloose P; Gandon-Laloum S; Borel Derlon A; Neerman-Arbez M
    Blood Coagul Fibrinolysis; 2008 Oct; 19(7):697-9. PubMed ID: 18832913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrinogen Lima: a homozygous dysfibrinogen with an A alpha-arginine-141 to serine substitution associated with extra N-glycosylation at A alpha-asparagine-139. Impaired fibrin gel formation but normal fibrin-facilitated plasminogen activation catalyzed by tissue-type plasminogen activator.
    Maekawa H; Yamazumi K; Muramatsu S; Kaneko M; Hirata H; Takahashi N; Arocha-Piñango CL; Rodriguez S; Nagy H; Perez-Requejo JL
    J Clin Invest; 1992 Jul; 90(1):67-76. PubMed ID: 1634621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Normal binding of calcium to five fibrinogen variants with mutations in the carboxy terminal part of the gamma-chain.
    Furlan M; Stucki B; Steinmann C; Jungo M; Lämmle B
    Thromb Haemost; 1996 Sep; 76(3):377-83. PubMed ID: 8883274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrinogen Matsumoto I: a gamma 364 Asp-->His (GAT-->CAT) substitution associated with defective fibrin polymerization.
    Okumura N; Furihata K; Terasawa F; Nakagoshi R; Ueno I; Katsuyama T
    Thromb Haemost; 1996 Jun; 75(6):887-91. PubMed ID: 8822581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An engineered fibrinogen variant AαQ328,366P does not polymerise normally, but retains the ability to form α cross-links.
    Park R; Ping L; Song J; Seo JY; Choi TY; Choi JR; Gorkun OV; Lord ST
    Thromb Haemost; 2013 Feb; 109(2):199-206. PubMed ID: 23224113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibrinogen Matsumoto III: a variant with gamma275 Arg-->Cys (CGC-->TGC)--comparison of fibrin polymerization properties with those of Matsumoto I (gamma364 Asp-->His) and Matsumoto II (gamma308 Asn-->Lys).
    Terasawa F; Okumura N; Higuchi Y; Ishikawa S; Tozuka M; Ishida F; Kitano K; Katsuyama T
    Thromb Haemost; 1999 May; 81(5):763-6. PubMed ID: 10365751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibrinogen Caracas V, an abnormal fibrinogen with an Aalpha 532 Ser-->Cys substitution associated with thrombosis.
    Marchi R; Lundberg U; Grimbergen J; Koopman J; Torres A; de Bosch NB; Haverkate F; Arocha Piñango CL
    Thromb Haemost; 2000 Aug; 84(2):263-70. PubMed ID: 10959699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluorogenic fibrinogen and fibrin facilitate macromolecular assembly and dynamic assay of picomolar levels of plasminogen activators under well mixed conditions.
    Wu JH; Diamond SL
    Thromb Haemost; 1995 Aug; 74(2):711-7. PubMed ID: 8585011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional characterization of fibrinogen Bicêtre II: a gamma 308 Asn-->Lys mutation located near the fibrin D:D interaction sites.
    Marchi RC; Carvajal Z; Boyer-Neumann C; Anglés-Cano E; Weisel JW
    Blood Coagul Fibrinolysis; 2006 Apr; 17(3):193-201. PubMed ID: 16575257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The mutation in fibrinogen Bicêtre II (gamma Asn308-->Lys) does not affect the binding of t-PA and plasminogen to fibrin.
    Grailhe P; Boyer-Neumann C; Haverkate F; Grimbergen J; Larrieu MJ; Anglés-Cano E
    Blood Coagul Fibrinolysis; 1993 Oct; 4(5):679-87. PubMed ID: 8292717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrinogen Matsumoto V: a variant with Aalpha19 Arg-->Gly (AGG-->GGG). Comparison between fibrin polymerization stimulated by thrombin or reptilase and fibrin monomer polymerization.
    Tanaka H; Terasawa F; Ito T; Tokunaga S; Ishida F; Kitano K; Kiyosawa K; Okumura N
    Thromb Haemost; 2001 Jan; 85(1):108-13. PubMed ID: 11204560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibrinopeptide A release is necessary for effective B:b interactions in polymerisation of variant fibrinogens with impaired A:a interactions.
    Soya K; Terasawa F; Okumura N
    Thromb Haemost; 2013 Feb; 109(2):221-8. PubMed ID: 23238100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new type of Ser substitution for gamma Arg-275 in fibrinogen Kamogawa I characterized by impaired fibrin assembly.
    Mimuro J; Kawata Y; Niwa K; Muramatsu S; Madoiwa S; Takano H; Sugo T; Sakata Y; Sugimoto T; Nose K; Matsuda M
    Thromb Haemost; 1999 Jun; 81(6):940-4. PubMed ID: 10404772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro fibrin clot formation and fibrinolysis using heterozygous plasma fibrinogen from gammaAsn319, Asp320 deletion dysfibrinogen, Otsu I.
    Terasawa F; Kani S; Hongo M; Okumura N
    Thromb Res; 2006; 118(5):651-61. PubMed ID: 16412498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Homophenotypic Aalpha R16H fibrinogen (Kingsport): uniquely altered polymerization associated with slower fibrinopeptide A than fibrinopeptide B release.
    Galanakis DK; Neerman-Arbez M; Scheiner T; Henschen A; Hubbs D; Nagaswami C; Weisel JW
    Blood Coagul Fibrinolysis; 2007 Dec; 18(8):731-7. PubMed ID: 17982313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of plasmin generation and clot lysis of plasma fibrinogen purified from a heterozygous dysfibrinogenemia, BbetaGly15Cys (Hamamatsu II).
    Kamijyo Y; Hirota-Kawadobora M; Yamauchi K; Terasawa F; Honda T; Ikeya M; Okumura N
    Blood Coagul Fibrinolysis; 2009 Dec; 20(8):726-32. PubMed ID: 19809304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.